APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastric Mucosal Protective Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Gastric Mucosal Protective Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025191 pages

Choose your research edition.

Industry ResearchGastric Mucosal Protective Drugs Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastric Mucosal Protective Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Gastric Mucosal Protective Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastric Mucosal Protective Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastric Mucosal Protective Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Gastric Mucosal Protective Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Gastric Mucosal Protective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gastric Mucosal Protective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gastric Mucosal Protective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Gastric Mucosal Protective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Gastric Mucosal Protective Drugs include Abbott, Takeda Pharmaceutical, Taiho Pharmaceutical, Sucralfate (Carafate), Pharmaking, Misoprostol (Cytotec), Eisai, Daewoong Pharmaceutical and Cadila Healthcare, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gastric Mucosal Protective Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastric Mucosal Protective Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastric Mucosal Protective Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gastric Mucosal Protective Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Gastric Mucosal Protective Drugs Segment by Company

Abbott

Takeda Pharmaceutical

Taiho Pharmaceutical

Sucralfate (Carafate)

Pharmaking

Misoprostol (Cytotec)

Eisai

Daewoong Pharmaceutical

Cadila Healthcare

Bismuth Subsalicylate (Pepto-Bismol)

AstraZeneca

Gastric Mucosal Protective Drugs Segment by Type

Oral Medicines

Injectable Medicines

Gastric Mucosal Protective Drugs Segment by Application

Child patients

Elderly patients

Youth patients

Infant patients

Gastric Mucosal Protective Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Mucosal Protective Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastric Mucosal Protective Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Mucosal Protective Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gastric Mucosal Protective Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Gastric Mucosal Protective Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Gastric Mucosal Protective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Gastric Mucosal Protective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Gastric Mucosal Protective Drugs Industry Trends Table 2. Gastric Mucosal Protective Drugs Industry Drivers Table 3. Gastric Mucosal Protective Drugs Industry Opportunities and Challenges Table 4. Gastric Mucosal Protective Drugs Industry Restraints Table 5. Global Gastric Mucosal Protective Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Gastric Mucosal Protective Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Gastric Mucosal Protective Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Gastric Mucosal Protective Drugs Sales Market Share by Manufacturers Table 9. Global Gastric Mucosal Protective Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Gastric Mucosal Protective Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Gastric Mucosal Protective Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Gastric Mucosal Protective Drugs Manufacturers, Product Type & Application Table 13. Global Gastric Mucosal Protective Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Gastric Mucosal Protective Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Medicines Table 17. Major Manufacturers of Injectable Medicines Table 18. Global Gastric Mucosal Protective Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Gastric Mucosal Protective Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global Gastric Mucosal Protective Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global Gastric Mucosal Protective Drugs Sales Market Share by Type (2021-2026) Table 22. Global Gastric Mucosal Protective Drugs Sales Market Share by Type (2027-2032) Table 23. Global Gastric Mucosal Protective Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Gastric Mucosal Protective Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global Gastric Mucosal Protective Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global Gastric Mucosal Protective Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Gastric Mucosal Protective Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Child patients Table 29. Major Manufacturers of Elderly patients Table 30. Major Manufacturers of Youth patients Table 31. Major Manufacturers of Infant patients Table 32. Global Gastric Mucosal Protective Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Gastric Mucosal Protective Drugs Sales by Application (2021-2026) & (K Units) Table 34. Global Gastric Mucosal Protective Drugs Sales by Application (2027-2032) & (K Units) Table 35. Global Gastric Mucosal Protective Drugs Sales Market Share by Application (2021-2026) Table 36. Global Gastric Mucosal Protective Drugs Sales Market Share by Application (2027-2032) Table 37. Global Gastric Mucosal Protective Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Gastric Mucosal Protective Drugs Revenue by Application (2021-2026) & (K Units) Table 39. Global Gastric Mucosal Protective Drugs Revenue by Application (2027-2032) & (K Units) Table 40. Global Gastric Mucosal Protective Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Gastric Mucosal Protective Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Gastric Mucosal Protective Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Gastric Mucosal Protective Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Gastric Mucosal Protective Drugs Sales Market Share by Region (2021-2026) Table 45. Global Gastric Mucosal Protective Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Gastric Mucosal Protective Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Gastric Mucosal Protective Drugs Sales by Country (2021-2026) & (K Units) Table 49. North America Gastric Mucosal Protective Drugs Sales by Country (2027-2032) & (K Units) Table 50. Europe Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Gastric Mucosal Protective Drugs Sales by Country (2021-2026) & (K Units) Table 52. Europe Gastric Mucosal Protective Drugs Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Gastric Mucosal Protective Drugs Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Gastric Mucosal Protective Drugs Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Gastric Mucosal Protective Drugs Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Gastric Mucosal Protective Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global Gastric Mucosal Protective Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Gastric Mucosal Protective Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Gastric Mucosal Protective Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Gastric Mucosal Protective Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Gastric Mucosal Protective Drugs Revenue Market Share by Region (2027-2032) Table 64. Abbott Company Information Table 65. Abbott Business Overview Table 66. Abbott Gastric Mucosal Protective Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Abbott Gastric Mucosal Protective Drugs Product Portfolio Table 68. Abbott Recent Development Table 69. Takeda Pharmaceutical Company Information Table 70. Takeda Pharmaceutical Business Overview Table 71. Takeda Pharmaceutical Gastric Mucosal Protective Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Takeda Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio Table 73. Takeda Pharmaceutical Recent Development Table 74. Taiho Pharmaceutical Company Information Table 75. Taiho Pharmaceutical Business Overview Table 76. Taiho Pharmaceutical Gastric Mucosal Protective Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Taiho Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio Table 78. Taiho Pharmaceutical Recent Development Table 79. Sucralfate (Carafate) Company Information Table 80. Sucralfate (Carafate) Business Overview Table 81. Sucralfate (Carafate) Gastric Mucosal Protective Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Sucralfate (Carafate) Gastric Mucosal Protective Drugs Product Portfolio Table 83. Sucralfate (Carafate) Recent Development Table 84. Pharmaking Company Information Table 85. Pharmaking Business Overview Table 86. Pharmaking Gastric Mucosal Protective Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pharmaking Gastric Mucosal Protective Drugs Product Portfolio Table 88. Pharmaking Recent Development Table 89. Misoprostol (Cytotec) Company Information Table 90. Misoprostol (Cytotec) Business Overview Table 91. Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Product Portfolio Table 93. Misoprostol (Cytotec) Recent Development Table 94. Eisai Company Information Table 95. Eisai Business Overview Table 96. Eisai Gastric Mucosal Protective Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Eisai Gastric Mucosal Protective Drugs Product Portfolio Table 98. Eisai Recent Development Table 99. Daewoong Pharmaceutical Company Information Table 100. Daewoong Pharmaceutical Business Overview Table 101. Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio Table 103. Daewoong Pharmaceutical Recent Development Table 104. Cadila Healthcare Company Information Table 105. Cadila Healthcare Business Overview Table 106. Cadila Healthcare Gastric Mucosal Protective Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Cadila Healthcare Gastric Mucosal Protective Drugs Product Portfolio Table 108. Cadila Healthcare Recent Development Table 109. Bismuth Subsalicylate (Pepto-Bismol) Company Information Table 110. Bismuth Subsalicylate (Pepto-Bismol) Business Overview Table 111. Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Product Portfolio Table 113. Bismuth Subsalicylate (Pepto-Bismol) Recent Development Table 114. AstraZeneca Company Information Table 115. AstraZeneca Business Overview Table 116. AstraZeneca Gastric Mucosal Protective Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. AstraZeneca Gastric Mucosal Protective Drugs Product Portfolio Table 118. AstraZeneca Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Gastric Mucosal Protective Drugs Distributors List Table 122. Gastric Mucosal Protective Drugs Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Gastric Mucosal Protective Drugs Product Image Figure 2. Global Gastric Mucosal Protective Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastric Mucosal Protective Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Gastric Mucosal Protective Drugs Sales (2021-2032) & (K Units) Figure 5. Global Gastric Mucosal Protective Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Gastric Mucosal Protective Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Medicines Image Figure 9. Injectable Medicines Image Figure 10. Global Gastric Mucosal Protective Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Gastric Mucosal Protective Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Gastric Mucosal Protective Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Gastric Mucosal Protective Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Gastric Mucosal Protective Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Gastric Mucosal Protective Drugs Revenue Market Share by Type (2021-2032) Figure 16. Child patients Image Figure 17. Elderly patients Image Figure 18. Youth patients Image Figure 19. Infant patients Image Figure 20. Global Gastric Mucosal Protective Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Gastric Mucosal Protective Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Gastric Mucosal Protective Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Gastric Mucosal Protective Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Gastric Mucosal Protective Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Gastric Mucosal Protective Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Gastric Mucosal Protective Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Gastric Mucosal Protective Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Gastric Mucosal Protective Drugs Sales Market Share by Country (2021-2032) Figure 40. China Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Gastric Mucosal Protective Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Gastric Mucosal Protective Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Gastric Mucosal Protective Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Gastric Mucosal Protective Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Gastric Mucosal Protective Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Gastric Mucosal Protective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Gastric Mucosal Protective Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Gastric Mucosal Protective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Gastric Mucosal Protective Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Gastric Mucosal Protective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Gastric Mucosal Protective Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Gastric Mucosal Protective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Gastric Mucosal Protective Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Gastric Mucosal Protective Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Medicines
  • Injectable Medicines
Applications
  • Child patients
  • Elderly patients
  • Youth patients
  • Infant patients
Companies covered
  • Abbott
  • Takeda Pharmaceutical
  • Taiho Pharmaceutical
  • Sucralfate (Carafate)
  • Pharmaking
  • Misoprostol (Cytotec)
  • Eisai
  • Daewoong Pharmaceutical
  • Cadila Healthcare
  • Bismuth Subsalicylate (Pepto-Bismol)
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gastric Mucosal Protective Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gastric Mucosal Protective Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Gastric Mucosal Protective Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Gastric Mucosal Protective Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Gastric Mucosal Protective Drugs Market Dynamics
  1. 2.1 Gastric Mucosal Protective Drugs Industry Trends
  2. 2.2 Gastric Mucosal Protective Drugs Industry Drivers
  3. 2.3 Gastric Mucosal Protective Drugs Industry Opportunities and Challenges
  4. 2.4 Gastric Mucosal Protective Drugs Industry Restraints
3 Gastric Mucosal Protective Drugs Market by Manufacturers
  1. 3.1 Global Gastric Mucosal Protective Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Gastric Mucosal Protective Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Gastric Mucosal Protective Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Gastric Mucosal Protective Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Gastric Mucosal Protective Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Gastric Mucosal Protective Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Gastric Mucosal Protective Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Gastric Mucosal Protective Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Gastric Mucosal Protective Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Gastric Mucosal Protective Drugs Tier 1, Tier 2, and Tier 3
4 Gastric Mucosal Protective Drugs Market by Type
  1. 4.1 Gastric Mucosal Protective Drugs Type Introduction
  2. 4.1.1 Oral Medicines
  3. 4.1.2 Injectable Medicines
  4. 4.2 Global Gastric Mucosal Protective Drugs Sales by Type
  5. 4.2.1 Global Gastric Mucosal Protective Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Gastric Mucosal Protective Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Gastric Mucosal Protective Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Gastric Mucosal Protective Drugs Revenue by Type
  9. 4.3.1 Global Gastric Mucosal Protective Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Gastric Mucosal Protective Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Gastric Mucosal Protective Drugs Revenue Market Share by Type (2021-2032)
5 Gastric Mucosal Protective Drugs Market by Application
  1. 5.1 Gastric Mucosal Protective Drugs Application Introduction
  2. 5.1.1 Child patients
  3. 5.1.2 Elderly patients
  4. 5.1.3 Youth patients
  5. 5.1.4 Infant patients
  6. 5.2 Global Gastric Mucosal Protective Drugs Sales by Application
  7. 5.2.1 Global Gastric Mucosal Protective Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Gastric Mucosal Protective Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Gastric Mucosal Protective Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Gastric Mucosal Protective Drugs Revenue by Application
  11. 5.3.1 Global Gastric Mucosal Protective Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Gastric Mucosal Protective Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Gastric Mucosal Protective Drugs Revenue Market Share by Application (2021-2032)
6 Global Gastric Mucosal Protective Drugs Sales by Region
  1. 6.1 Global Gastric Mucosal Protective Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastric Mucosal Protective Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Gastric Mucosal Protective Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Gastric Mucosal Protective Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Gastric Mucosal Protective Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Gastric Mucosal Protective Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Gastric Mucosal Protective Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Gastric Mucosal Protective Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Gastric Mucosal Protective Drugs Revenue by Region
  1. 7.1 Global Gastric Mucosal Protective Drugs Revenue by Region
  2. 7.1.1 Global Gastric Mucosal Protective Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Gastric Mucosal Protective Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Gastric Mucosal Protective Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Gastric Mucosal Protective Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Gastric Mucosal Protective Drugs Revenue (2021-2032)
  8. 7.2.2 North America Gastric Mucosal Protective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Gastric Mucosal Protective Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Gastric Mucosal Protective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Gastric Mucosal Protective Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Gastric Mucosal Protective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Gastric Mucosal Protective Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Gastric Mucosal Protective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Gastric Mucosal Protective Drugs Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Takeda Pharmaceutical
  8. 8.2.1 Takeda Pharmaceutical Company Information
  9. 8.2.2 Takeda Pharmaceutical Business Overview
  10. 8.2.3 Takeda Pharmaceutical Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
  12. 8.2.5 Takeda Pharmaceutical Recent Developments
  13. 8.3 Taiho Pharmaceutical
  14. 8.3.1 Taiho Pharmaceutical Company Information
  15. 8.3.2 Taiho Pharmaceutical Business Overview
  16. 8.3.3 Taiho Pharmaceutical Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Taiho Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
  18. 8.3.5 Taiho Pharmaceutical Recent Developments
  19. 8.4 Sucralfate (Carafate)
  20. 8.4.1 Sucralfate (Carafate) Company Information
  21. 8.4.2 Sucralfate (Carafate) Business Overview
  22. 8.4.3 Sucralfate (Carafate) Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sucralfate (Carafate) Gastric Mucosal Protective Drugs Product Portfolio
  24. 8.4.5 Sucralfate (Carafate) Recent Developments
  25. 8.5 Pharmaking
  26. 8.5.1 Pharmaking Company Information
  27. 8.5.2 Pharmaking Business Overview
  28. 8.5.3 Pharmaking Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pharmaking Gastric Mucosal Protective Drugs Product Portfolio
  30. 8.5.5 Pharmaking Recent Developments
  31. 8.6 Misoprostol (Cytotec)
  32. 8.6.1 Misoprostol (Cytotec) Company Information
  33. 8.6.2 Misoprostol (Cytotec) Business Overview
  34. 8.6.3 Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Product Portfolio
  36. 8.6.5 Misoprostol (Cytotec) Recent Developments
  37. 8.7 Eisai
  38. 8.7.1 Eisai Company Information
  39. 8.7.2 Eisai Business Overview
  40. 8.7.3 Eisai Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eisai Gastric Mucosal Protective Drugs Product Portfolio
  42. 8.7.5 Eisai Recent Developments
  43. 8.8 Daewoong Pharmaceutical
  44. 8.8.1 Daewoong Pharmaceutical Company Information
  45. 8.8.2 Daewoong Pharmaceutical Business Overview
  46. 8.8.3 Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
  48. 8.8.5 Daewoong Pharmaceutical Recent Developments
  49. 8.9 Cadila Healthcare
  50. 8.9.1 Cadila Healthcare Company Information
  51. 8.9.2 Cadila Healthcare Business Overview
  52. 8.9.3 Cadila Healthcare Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cadila Healthcare Gastric Mucosal Protective Drugs Product Portfolio
  54. 8.9.5 Cadila Healthcare Recent Developments
  55. 8.10 Bismuth Subsalicylate (Pepto-Bismol)
  56. 8.10.1 Bismuth Subsalicylate (Pepto-Bismol) Company Information
  57. 8.10.2 Bismuth Subsalicylate (Pepto-Bismol) Business Overview
  58. 8.10.3 Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Product Portfolio
  60. 8.10.5 Bismuth Subsalicylate (Pepto-Bismol) Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Gastric Mucosal Protective Drugs Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gastric Mucosal Protective Drugs Value Chain Analysis
  2. 9.1.1 Gastric Mucosal Protective Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gastric Mucosal Protective Drugs Production Mode & Process
  6. 9.2 Gastric Mucosal Protective Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gastric Mucosal Protective Drugs Distributors
  9. 9.2.3 Gastric Mucosal Protective Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst